RhinoCyte

About:

RhinoCyte develops and commercializes diagnostic tools and therapies for the stem cell treatment of neurological diseases.

Website: http://www.rhinocyte.com

Top Investors: Keyhorse Capital (KSTC), Kentucky Seed Capital Fund, Queen City Angels

Description:

RhinoCyte engages in the development and commercialization of diagnostic tools and therapies for stem cell treatment of multiple degenerative and traumatic neurological diseases. Its technology facilitates functional recovery in patients, including therapeutic stem cell transplantation with cells from the patient's own nasal cavity eliminating the need for immunosuppressive therapy. The company's technology is used to treat conditions, such as Parkinson's disease, Multiple Sclerosis, Alzheimer's disease, and spinal cord injuries. RhinoCyte, Inc. was founded in 2005 and is based in Louisville, Kentucky.

Total Funding Amount:

$4.7M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Louisville, Kentucky, United States

Founded Date:

2005-01-01

Contact Email:

info(AT)rhinocyte.com

Founders:

Fred Roisen

Number of Employees:

1-10

Last Funding Date:

2015-10-07

IPO Status:

Private

Industries:

© 2025 bioDAO.ai